Trial reportPediatric blood & cancer2011
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.
Trial report in Pediatric blood & cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00030394 (A Phase II Study of Gleevec in Ph+ Chronic Phase Chronic Myelogenous Leukemia), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Gleevec in Ph+ Chronic Phase Chronic Myelogenous Leukemia
Who cites it
22 citing papers in PubMed, 59 citations in OpenAlex.
- Trial
- Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.Leukemia · 2018Trial
- Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.Medical science monitor : international medical journal of experimental and clinical research · 2012Trial
- Article
- Article
- Review
- Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)-Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.Case reports in oncological medicine · 2025Article
- Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan.British journal of cancer · 2023Article
- Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials.Frontiers in oncology · 2023Review
- Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas.Cancers · 2022Review
- Tyrosine Kinase Inhibitors and Beyond for Chronic Myeloid Leukemia in Children.Paediatric drugs · 2021Review
- Chronic Myelogenous Leukemia in Childhood.Current oncology reports · 2021Review
- Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML.International journal of molecular sciences · 2020Review
- Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group.Pediatric blood & cancer · 2019Review
- Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.Blood · 2016Article
- Treatment of chronic phase chronic myeloid leukemia with imatinib.Indian journal of pediatrics · 2015Article
- Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country.International journal of hematology · 2014Article
- Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.Pediatric blood & cancer · 2013Review
- Management of chronic myeloid leukemia in childhood.Current hematologic malignancy reports · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 2 countries.
Funding
Abstract
purposeTo determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML).
methodsThis was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at 340 mg/m² without interruption in the absence of toxicity.
resultsFifty-one children received 978 28-day courses of imatinib. The most common toxicities encountered were hematologic. Forty-one patients (80%) achieved a complete hematologic response by the end of course 2. Nineteen children (38%) obtained a complete cytogenetic response (CCyR) at the end of course 3. Overall, 72% achieved CCyR at a median time of 5.6 months. The rate of complete molecular response (>3 log reduction) was 27%. Progression-free and overall survival at 3 years were 72% ± 6.4% and 92% ± 3.9%, respectively.
conclusionsDaily oral imatinib at a dose of 340 mg/m² is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.